N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinea CAS 152460-10-1
Commercial Supple Imatinib Mesylate et intermedia:
Imatinib Mesylate CAS: 220127-57-1
N-(2-Methyl-5-nitrophenyl) -4-(pyridin-3-yl) pyrimidin-2-amine CAS: 152460-09-8
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinea CAS:
4-[(4-Methylpiperazin-1-yl) methyl] acidum benzoicum dihydrochloridum CAS: 106261-49-8
| Nomen chemicum | N. |
| Synonyma | Imatinib Mesylate Intermedia;2-(5-Amino-2-methylanilino)-4-(3-pyridyl) pyrimidine |
| CAS Number | 152460-10-1 |
| CATTUS Number | RF-PI230 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C16H15N5 |
| M. Pondus | 277.32 |
| Liquescens punctum | 133.0-135.0℃ |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Lux Aliquam to Yellow pulveris in Crystal |
| Puritas / Analysis Methodus | ≥98.0% |
| Damnum in Siccatio | ≤0.50% |
| Requiesce in ignitio | ≤0.50% |
| Totalis immunditias | ≤2.0% |
| Maximum Impuritas | ≤1.0% |
| Metalla gravis | ≤20ppm |
| Test Standard | Enterprise Standard |
| Consuetudinem | Imatinib Mesylate (CAS: 220127-57-1) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, umore et peste infestatione.
Shanghai Ruifu Chemical Co., Ltd. est primarium fabrica et supplementum N(5-Amino-2-methylphenyl) -4-(3-pyridyl)-2-pyrimidineae (CAS: 152460-10-1) cum qualitate alta .
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinea (CAS: 152460-10-1) media est typice in synthesi Imatinib Mesylate (CAS: 220127-57-1 API.
Imatinib mesylatum parvum est moleculum quod kinasum c-Abl interdum tyrosinum vetat, kinasum speciei momenti ad multiplicationem myelogenae leukemia longae (CML).Eventus translocatio inter chromosomatum 9 et 22 chromosomatum Philadelphiae gignit, quod deinde fusionem interdum Bcr-Abl producit cum actione kinasi aberrantis quae celerem cellulam multiplicationem promovet.Imatinib mesylate ligat hanc kinasem crucialem, claudicans CML incrementum affinis.Imatinib mesylate inhibere PDGFR et kinases tyrosinas cum c-Kit, ulterius inhibere monstratum est.Formulae Imatinib mesylate continentur adhibitae in curatione carcinomata varia.
Imatinib mesylate est tyrosine kinase inhibitor.Maxime specifica pro BCR-ABL, enzyme cum myelogeno leukemia chronico (CML) et quibusdam formis lymphoblasticis leukemia acutis (ALL).Inhibitor inhibitor potens et selectivus v-Abl tyrosinus est (IC50 = 38 nM).item nia PDGFR et c- ornamentum.Exhibet selectivity pro v-Abl super tabellam aliorum tyrosinae et serinae/threoninae interdum kinases.Selecte vetat PDGF incrementum excita- v-abl transformatum cellularum PB-3 et v-sis transformatorum BALB/c 3T3 cellulae in vitro.Antitumor effectus exhibet mures portantes AMuLV vel BABL/c 3T3 cellulas v-sis.Replicatio inhibet SARS-CoV et MERS-CoV in vitro (valores EC50 9.823 et 17.689 μM, respective).
![4-[(4-Methylpiperazin-1-yl) methyl]acidi dihydrochloridi benzoici CAS 106261-49-8 Imatinib Mesylate intermedia High Munditia](https://www.ruifuchemical.com/uploads/d1fa2a19-300x300.jpg)